You are on page 1of 13

Consultant: Volume 56 - Issue 3 - March 2016

Acute Hypertension: Hypertensive Urgency

and Hypertensive Emergency
March 10, 2016

Bookmark this page


Gregary D. Marhefka, MD


Consultant. 2016;56(3):222-232.

ABSTRACT: Acute hypertensionblood pressure greater than 180/120 mm Hgcan be

classified as either hypertensive urgency or hypertensive emergency. Hypertensive urgency has
no associated target organ damage, whereas hypertensive emergency can feature neurologic,
aortic, cardiac, renal, hematologic, and/or pregnancy-related damage. Little evidence-based
research exists about treatment. Intravenous antihypertensive pharmacotherapy is indicated only
for hypertensive emergency, with the use of specific agents tailored to the type of organ damage.
Several US and European guidelines provide recommendations for the diagnosis and
management of hypertensive urgency and hypertensive emergency. This review summarizes
what is known about managing hypertensive urgency and emergency, with an emphasis on
guideline-directed therapy.

KEYWORDS: Acute hypertension, hypertensive urgency, hypertensive emergency,

hypertensive crisis, malignant hypertension

"There is some truth in the saying that the greatest danger to a man with a high blood pressure
lies in its discovery, because then some fool is certain to try and reduce it, said British
physician John Hay, MD, in 1931.1 We have learned a great deal about acute hypertension in the
85 years since Dr Hay was quoted. Nevertheless, despite dramatic advances in modern medicine,
a significant void still exists in its evidence-based management.

Acute hypertension is common and can be divided into hypertensive urgency or hypertensive
emergency, which is blood pressure greater than 180/120 mm Hg without or with target organ
damage, respectively. In a recent retrospective study of more than 1.2 million patient hospital
admissions from 114 US hospitals, Shorr and colleagues2 reported that 13.8% were found to
have acute hypertension in the emergency department (ED). From 2006 to 2011, visits to EDs
for essential hypertension have increased by 25%.3
The paucity of data about hypertensive urgency and emergency is reflected in the fact that the
latest 2014 guideline for the management of high blood pressure in adults from the Eighth Joint
National Committee (JNC 8) does not even mention acute hypertension or hypertensive urgency
or emergency.4


Definition of hypertensive urgency. Because the JNC 8 does not comment on hypertensive
urgency in its 2014 guideline, one must refer to expert opinion from the 2003 JNC 7 guideline.5
Hypertensive urgency is defined as a blood pressure greater than 180/120 mm Hg in the absence
of progressive target organ dysfunction. These patients are often therapy-nonadherent or
inadequately treated. They may present with headache, shortness of breath, epistaxis, or anxiety
but often are asymptomatic.

The JNC 7 notes, Unfortunately, the term urgency has led to overly aggressive management of
many patients with severe, uncomplicated hypertension.5 The American College of Emergency
Physicians (ACEP) 2013 policy statement6 chooses the phrase asymptomatic elevated blood
pressure rather than hypertensive urgency. The colleges policy statement notes that most
clinical trials use a blood pressure above 180/100 mm Hg, but they chose to define asymptomatic
elevated blood pressure as that consistent with JNC 7s stage 2 hypertension, 160/100 mm Hg or
greater. The 2013 hypertension management guidelines from the European Society of
Hypertension (ESH) and the European Society of Cardiology (ESC) define hypertensive urgency
as blood pressure greater than 180/120 mm Hg without acute organ damage7 (Table 1).
Uses phrase asymptomatic elevated blood pressure instead of hypertensive urgency.

Abbreviations: ACCF/AHA, American College of Cardiology Foundation/American Heart

Association; ACEP, American College of Emergency Physicians;
ACOG, American College of Obstetrics and Gynecology; AHA/ASA, American Heart
Association/American Stroke Association; BP, blood
pressure; ESC/ESH, European Society of Cardiology/European Society of Hypertension; HR,
heart rate; HTN, hypertension; JNC 7, Seventh Joint
National Committee; JNC 8, Eighth Joint National Committee; MAP, mean arterial pressure;
SBP, systolic blood pressure; STEMI, ST-segment
elevation myocardial infarction; tPA, tissue plasminogen activator.

Treatment of hypertensive urgency. Dr Hays 1931 statement is apropos today as it applies to

hypertensive urgency. According to expert opinion from the 2003 JNC 7, no evidence exists that
specific treatment for hypertensive urgency is warranted.5 Patients likely will need to have their
medications adjusted or reinitiated in the presence of nonadherence, but most importantly,
patients being discharged from the ED should have a confirmed follow-up appointment in the
next few days.

The ACEP 2013 policy statement on asymptomatic elevated blood pressure recommends against
routine screening for acute target organ injury unless the patient is less likely to follow up, or if
there is question of admission to the hospital, in which case screening for an elevated creatinine
level is suggested.6 In primary care, JNC 7 guidelines suggest a thorough physical examination
including assessment of bilateral blood pressures, body mass index, and optic fundi; palpation
and auscultation of carotid arteries, femoral arteries, abdominal aorta, thyroid, heart, lungs,
abdomen (for enlarged kidneys or distended bladder), and extremities (for edema and pulses);
and a neurologic examination. Screening tests should include electrocardiography for left
ventricular hypertrophy, urinalysis, and serum glucose, hematocrit, potassium, creatinine, and
lipid levels.5

The 2013 ESH/ESC guideline states, Isolated large BP elevations without acute [organ
dysfunction] should not be considered an emergency.7 They recommend reinstitution or
intensification of oral drug therapy without any mention of specific agents (Table 1).

In 1989, Zeller and colleagues8 prospectively followed 64 asymptomatic ED patients with severe
hypertension (diastolic blood pressure of 116-139 mm Hg) not recently on antihypertensives.
Each patient initially had received oral clonidine and hydrochlorothiazide, then each was
randomized to 1 of 3 treatment arms: (1) up to 4 hourly doses of oral clonidine until a 20 mm Hg
drop in diastolic pressure or to a diastolic pressure of 105 mm Hg, followed by maintenance
therapy; (2) an initial dose of oral clonidine followed by hourly oral placebo and subsequent
maintenance therapy; or (3) no serial doses and only oral maintenance therapy. They found no
difference in the time required to achieve blood pressure control between groups 1 and 2, and no
difference at 24 hours in pressure reduction between groups 1, 2, and 3. Of the 44 patients who
followed up at 1 week, blood pressure had been adequately controlled across all groups, with no
difference between groups.

Levy and colleagues9 retrospectively reported on 1016 patients discharged from an urban
teaching hospital ED in 2008 with a primary diagnosis of hypertensive urgency (>180/100 mm
Hg) without target organ damage. A total of 435 patients (42.8%) (average age, 49.2 years;
94.5% African American) were treated, mostly with oral clonidine (in 88.5% of those treated).
The authors observed that most of the treated patients had a history of hypertension (93.1% vs
84.3%) and a higher initial mean blood pressure (202/115 vs 185/106 mm Hg). They found no
significant difference between treated patients and untreated patients in ED revisits at 24 hours
(4.4% vs 2.4%) and at 30 days (18.9% vs 15.2%), or mortality at 30 days (0.2% vs 0.2%) and 1
year (2.1% vs 1.6%).

Grassi and colleagues10 studied 549 ED patients (average age 59 years; 51% men) with
asymptomatic blood pressure greater than 180/100 mm Hg, without preexisting cardiovascular,
cerebrovascular, or renovascular disease. All patients were placed in a quiet room for 30 minutes
of rest; 175 patients (31.9%) had a significant reduction in blood pressure of at least 20/10 mm
Hg to below 180/100 mm Hg with rest alone. The remaining patients then were given oral
amlodipine, perindopril, or labetalol (decided by the attending physician of record), of which 296
of 394 (75%) had a significant reduction in blood pressure of at least 20/10 mm Hg to below
180/100 mm Hg. There were no complications noted in any of the groups at follow-up within 48
to 72 hours.

These studies demonstrate the safety and importance of rest and oral antihypertensive therapy
with close outpatient follow-up for the treatment of hypertensive urgency.


Definition of hypertensive emergency. Because JNC 8 guidelines do not make reference to

hypertensive emergencies, one must refer to the 2003 JNC 7 guidelines, which define
hypertensive emergency as a blood pressure greater than 180/120 mm Hg in the presence of
target organ damage.5 The 2013 ACEP guidelines6 do not have a specific policy regarding
hypertensive emergency. The ESH/ESC guideline7 defines hypertensive emergency as a blood
pressure greater than 180/120 mm Hg in the presence of impending or progressive organ
damage. The 2015 American College of Obstetrics and Gynecology (ACOG) guidelines define
hypertensive emergency in pregnancy as acute-onset, severe hypertension of 160/110 mm Hg or
above persisting more than 15 minutes.11 The type of target organ damage includes
encephalopathy (including posterior reversible encephalopathy syndrome [PRES]), stroke,
seizure, retinopathy, acute aortic dissection, acute myocardial infarction (MI), acute heart
failure/acute pulmonary edema, acute renal failure, microangiopathic hemolytic anemia, severe
preeclampsia, HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome, and
eclampsia (Table 2).
There is no specific ICD-10 code for hypertensive urgency or hypertensive
emergency. These are considered synonymous under ICD-10 code I10, primary
(essential) hypertension.
Abbreviations: HELLP, hemolysis, elevated liver enzymes, low platelet count;
ICD-10, 10th revision of the International Statistical Classification of Diseases and
Related Health Problems; NSTEMI, non-ST segment elevation myocardial infarction;
PRES, posterior reversible encephalopathy syndrome.

Treatment of hypertensive emergency. The goal of treatment of hypertensive emergency is to

reduce the blood pressure safely enough to reverse the target organ damage without resulting in
detrimental sequelae from iatrogenically caused organ malperfusion. Organs such as the brain,
heart, and kidneys contain a microcirculation that is sensitive to broad fluctuations in systemic
blood pressure.5 In chronic hypertension, a rightward shift in the pressure-flow autoregulation
curve helps protect the brain, for example, from the deleterious effects of chronic hypertension
(Figure). In the setting of chronic hypertension, a sudden and severe reduction in blood pressure
to what would otherwise be considered normal could result in malperfusion. Therefore, the vast
majority of patients with hypertensive emergency should be managed in an intensive care unit
(ICU), where they can be closely monitored for signs of iatrogenic target organ damage from
overly aggressive blood pressure lowering and/or progression of the original target organ damage
secondary to inadequate blood pressure control.

Figure. Cerebral microvasculature autoregulation. In a chronic severely hypertensive

patient, acute reduction in blood pressure to the normal level could result in
cerebral malperfusion (black arrows). Abbreviations: HTN, hypertension; MAP, mean
arterial pressure.
In these situations, intra-arterial blood pressure monitoring often is required, especially if the
patient is on potent intravenous (IV) antihypertensive therapy. Referring to the JNC 7 expert
opinion,5 mean arterial blood pressure (MAP) should be reduced by 25% or less within the first
hour. Between hours 2 to 6, the target blood pressure is 160/100 to 160/110 mm Hg, followed by
gradual normalization over 24 to 48 hours.5 The 2013 ESH/ESC guideline7 recommends
reducing blood pressure by less than 25% within the first hour and then subsequent cautious
reduction thereafter.

The one diagnosis that mandates an immediate rather than gradual reduction to normal blood
pressure levels is acute aortic syndrome (Table 1).12,13

Neurologic Damage

Examples of neurologic damage in acute hypertensive emergencies are hypertensive

encephalopathy, including PRES, acute stroke, seizure, and retinopathy. The medications of
choice for treating neurologic emergencies are those that do not increase intracranial pressure
(Table 3). The IV dihydropyridine calcium-channel blockers nicardipine and clevidipine, or the
IV dual 1- and 1/2-adrenergic receptor blocker labetalol, are generally well tolerated and are
the medications of choice.

Abbreviation: dP/dtmax, change in ventricular pressure over change in time.

Nitroprusside, nitroglycerin, and hydralazine all have the potential to increase intracranial
pressure and therefore are generally contraindicated in this setting. Hydralazine in particular as
an as-needed, bolus IV medication has little role in any acute hypertension treatment, except
perhaps for pregnancy-related acute hypertension, owing to the unpredictability of response and
prolonged duration of action.14

PRES is a neuroradiologic and clinical diagnosis that typically is associated with hypertensive
encephalopathy but also can be seen in pregnancy-associated, acute-onset, severe hypertension
syndromes (preeclampsia, eclampsia, HELLP syndrome) and with certain organ transplant
immunosuppressive medications such as tacrolimus and cyclosporine.15

The 2013 American Heart Association/American Stroke Association (AHA/ASA) guidelines for
the early management of patients with acute ischemic stroke16 recommend treatment of blood
pressures greater than 220/120 mm Hg in the setting of acute ischemic stroke. If the use of tissue
plasminogen activator (tPA) is indicated, the goal is to reduce blood pressure in these patients to
less than 185/110 mm Hg before tPa administration in order to reduce the risk of hemorrhagic
conversion. For systolic blood pressure greater than 140 mm Hg but less than 220 mm Hg, there
is no proof that any treatment is beneficial. If systolic blood pressure is less than 120 mm Hg in
the setting of acute ischemic stroke, the guidelines recommend placing the patient flat and
providing isotonic saline to minimize the potential for cerebral malperfusion. As the AHA/ASA
guidelines note, Unfortunately, an ideal blood pressure range has not yet been scientifically

Seizures are a possible symptom of hypertensive encephalopathy and/or acute stroke and are
treated with benzodiazepines or antiepileptic agents. Retinopathy is a relatively common
complication of hypertension. Historically, retinopathy, along with acute nephropathy, was the
first organ pathology identified in malignant hypertension described in the 1920s.17 These
chronic hypertensive conditions had been considered malignant because of the associated high
mortality ratesof the 81 patients observed by Keith and colleagues,17 91% died within 4 years,
and the average lifespan of these patients was 8 months.

Hypertensive emergencies can be associated with acute retinopathy or acute choroidopathy and
associated vision loss. Involvement of the choroid typically is a sign of acute, dramatic rise in
blood pressure, often in a young person, in the setting of hypertensive emergency.18

Aortic Damage

Type A aortic dissection involves the ascending aorta and is a surgical emergency requiring
immediate operative repair, given that the mortality rate of nonsurgically treated cases is 50%
within the first 48 hours. Type B aortic dissection involves only the descending thoracic aorta
and generally is treated medically unless there are signs of organ malperfusion on presentation,
such as spinal cord or abdominal viscera ischemia.
The 2010 American College of Cardiology Foundation (ACCF) and AHA task force guidelines
for the diagnosis and management of thoracic aortic disease recommend reducing the velocity of
ventricular contraction (dP/dtmax), the rate of ventricular contraction, and the blood pressure with
-blockers, targeting a heart rate of less than 60 beats/min and a systolic blood pressure between
100 and 120 mm Hg while maintaining adequate organ perfusion.12

The 2014 ESC guidelines on the diagnosis and treatment of aortic diseases recommend treatment
with IV -blockers to reduce heart rate and lower systolic blood pressure to 100 to 120 mm Hg
(Table 1).13 It is essential to start with a negative inotrope such as esmolol, because starting with
vasodilator therapy actually may increase dP/dt and therefore the sheer stresses on the acutely
injured aorta, leading to dissection progression and rupture. After -blockers have been
maximized, pure vasodilator medications such as nicardipine, clevidipine, nitroprusside, or
nitroglycerin may be needed to achieve the target blood pressure (Table 3).

Acute aortic syndromes also are unique because, unlike with other hypertensive emergencies, the
goal is to reduce systolic blood pressure to 100 to 120 mm Hg as quickly as possible, not only by
25% in the first hour or so. This requires strict ICU-level monitoring for sequelae of overly rapid
reduction of blood pressure that can occur due to potential loss of microvasculature
autoregulation at suddenly lower blood pressures. If this occurs, finding a median blood pressure
that reduces dP/dt on the injured aorta but allows other organ perfusion is individualized by

Cardiac Damage

Acute hypertension sometimes can be associated with acute MI, acute heart failure, or acute
pulmonary edema. In the differential diagnosis of ST segment elevation MI (STEMI), one must
always remember the possibility of acute type A aortic dissection with the dissection flap
occluding right coronary artery flow or, more rarely, left coronary artery flow.19

For hypertensive emergency with acute MI not associated with type A aortic dissection,
treatment with nitroglycerin is indicated, along with goal-directed therapies for non-ST segment
elevation MI or STEMI (Table 3). Nitroglycerin should not be used in cases of suspected right
ventricular infarction or if the patient recently has taken a phosphodiesterase type 5 inhibitor for
erectile dysfunction within the preceding 24 to 48 hours.

Per the 2013 ACCF/AHA guideline for the STEMI management,20 fibrinolytic therapy is
absolutely contraindicated in severe uncontrolled hypertension greater than 180/110 mm Hg that
is unresponsive to emergency medical therapy (Table 3). If there is severe hypertension greater
than 180/110 mm Hg at the time of admission, fibrinolytic therapy is relatively contraindicated
(Table 1). In addition to IV nitroglycerin, an IV -blocker (eg, metoprolol) also is reasonable for
ongoing hypertension or ischemia in the absence of acute heart failure, low cardiac output, or
bradyarrhythmias. Nitroprusside should be used carefully if at all in the setting of acute coronary
syndrome due to its potential for inducing coronary steal. The true clinical significance of this
potential complication is unknown.21
In acute heart failure, IV diuretics and IV nitroglycerin or nitroprusside are indicated. The IV
negative inotropes such as esmolol, labetalol, and diltiazem are generally contraindicated in
acute heart failure, because they could induce a low cardiac output state. Furthermore, the
dihydropyridine calcium-channel blockers nicardipine and clevidipine also have some degree of
negative inotrope properties and should be used sparingly in the setting of acute heart failure.
High-dose nicardipine continuous drips also contain a significant volume of fluid, which also can
potentiate heart failure.

Renal Damage

Acute kidney injury in hypertensive emergency is relatively common. In a prospective, cross-

sectional study, Derhaschnig and colleagues22 found that levels of creatinine, blood urea
nitrogen, cystatin C, and neutrophil gelatinase-associated lipocalin were significantly higher and
the estimated glomerular filtration rate was significantly lower in hypertensive emergency
patients compared with urgencies or control patients (59 patients in all; patients with chronic
kidney disease were excluded).

Acute or preexisting renal impairment may predispose to the development of hypertensive

emergency, and hypertensive emergency likewise may lead to direct kidney injury. The IV
calcium-channel blockers nicardipine or clevidipine, or the dual 1- and 1/2-adrenergic receptor
blocker labetalol, are acceptable medications for blood pressure control in acute kidney injury in
the setting of hypertensive emergency (Table 3). IV nitroprusside also is very effective, but its
limitation is in its renal clearance and the potential for thiocyanate poisoning or life-threatening
cyanide toxicity.

A less common renal hypertensive emergency is scleroderma renal crisis, which is acute
hypertension seen in approximately 5% of patients with systemic sclerosis.23 Scleroderma renal
crisis is the new onset of accelerated hypertension in association with oliguric or anuric acute
renal failure.24 It also can be associated with acute heart failure, encephalopathy, and thrombotic
microangiopathy. Pathologically, it is associated with autoimmunity, vasculopathy, and fibrosis.
Regardless of renal failure and function, treatment is with angiotensin-converting enzyme
inhibitors (ACEIs) (Table 3). Acutely, oral captopril is the medication of choice, regardless of
the serum creatinine level. If needed, hemodialysis may be instituted. Prognosis after an episode
of scleroderma renal crisis is significantly worse, with a 5-year survival rate of 65%.24 Lifelong
ACEI therapy is indicated following an episode, but interestingly, ACEI therapy before an
episode of scleroderma renal crisis has never proven to be preventive.

Hematologic Damage

A rare but often forgotten pathophysiologic process in hypertensive emergency is

microangiopathic hemolytic anemia (MAHA).25 Described in malignant hypertension, MAHA is
characterized by coinciding thrombocytopenia and elevated serum lactate dehydrogenase that
frequently is associated with renal or cerebral dysfunction. Microscopically, there is fibrinoid
necrosis with fibrin and platelet thrombi in the lumina of small vessels, resulting in luminal
narrowing and intravascular fragmentation of red blood cells with consumption of platelets.26
Treatment is supportive, with blood pressure control typically resulting in resolution. Acutely,
any of the IV agents me be used, tailoring therapy to any coexisting conditions (Table 3).


The 2015 ACOG guidelines11 define pregnancy and postpartum acute-onset, severe hypertension
as blood pressure of 160/110 mm Hg or greater persisting more than 15 minutes (Table 1). It is
associated with severe preeclampsia, eclampsia, and HELLP syndrome.11 It can occur in the
second half of pregnancy in previously nonhypertensive women, or in women with preexisting
hypertension who develop a superimposed preeclampsia with acutely worsening hypertension. If
a pregnant woman is found in the office to have acute-onset, severe hypertension of 160/110 mm
Hg or higher for more than 15 minutes, she should be referred immediately to the hospital.

While monitoring the fetus, the recommended first-line agents are IV labetalol, IV hydralazine,
or oral nifedipine (Table 3). Magnesium sulfate is not an antihypertensive medication but is used
to prophylactically reduce seizure risk in preeclampsia or to treat seizures in eclampsia.
Hydralazine can induce maternal hypotension. Labetalol can result in neonatal bradycardia and
should be avoided in patients with heart failure or asthma. Nifedipine can lead to maternal
tachycardia and hypotension.11


There are no coding diagnoses specific to hypertensive urgency or hypertensive emergency in

the 10th revision of the International Statistical Classification of Diseases and Related Health
Problems (ICD-10). These diagnoses are considered synonyms under Essential (Primary)
Hypertension, ICD-10 code I10. Table 2 lists some of the ICD-10 billing codes related to target
organ damage and illnesses seen in hypertensive emergency.


Acute hypertension is categorized as hypertensive urgency or hypertensive emergency depending

on the absence or presence of target organ damage, respectively. Few data exist regarding its
evidence-based management. Current US and European guidelines recommend initiation,
reinitiation, or intensification of oral antihypertensive therapy for hypertensive urgency, whereas
controlled IV antihypertensive therapy is reserved for hypertensive emergencies.

The optimal IV medication and the rapidity with which optimal blood pressure is achieved
depend on the type of end-organ damage.

Gregary D. Marhefka, MD, is the associate director of the Cardiovascular Intensive Care Unit
and an associate professor of medicine in the Department of Medicine, Division of Cardiology,
at the Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia,

1. Hay J. A British Medical Association lecture on the significance of a raised blood
pressure. Br Med J. 1931;2(3679):43-47.
2. Shorr AF, Zilberberg MD, Sun X, Johannes RS, Gupta V, Tabak YP. Severe acute
hypertension among inpatients admitted from the emergency department. J Hosp Med.
3. Skinner HG, Blanchard J, Elixhauser A. Trends in Emergency Department Visits, 2006
2011. Rockville, MD: Agency for Healthcare Research and Quality. HCUP Statistical
Brief 179.
Departmen.... Published September 2014. Accessed March 3, 2016.
4. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management
of high blood pressure in adults: report from the panel members appointed to the Eighth
Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
5. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education
Program Coordinating Committee. Seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension.
6. Wolf SJ, Lo B, Shih RD, Smith MD, Fesmire FM; American College of Emergency
Physicians Clinical Policies Committee. Clinical policy: critical issues in the evaluation
and management of adult patients in the emergency department with asymptomatic
elevated blood pressure. Ann Emerg Med. 2013; 62(1):59-68.
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management
of arterial hypertension: the task force for the management of arterial hypertension of the
European Society of Hypertension (ESH) and of the European Society of Cardiology
(ESC). J Hypertens. 2013;31(7):1281-1357.
8. Zeller KR, Von Kuhnert L, Matthews C. Rapid reduction of severe asymptomatic
hypertension: a prospective, controlled trial. Arch Intern Med. 1989; 149(10):2186-2189.
9. Levy PD, Mahn JJ, Miller J, et al. Blood pressure treatment and outcomes in hypertensive
patients without acute target organ damage: a retrospective cohort. Am J Emerg Med.
10. Grassi D, OFlaherty M, Pellizzari M, et al; Group of Investigators of the REHASE
Program. Hypertensive urgencies in the emergency department: evaluating blood
pressure response to rest and to antihypertensive drugs with different profiles. J Clin
Hypertens (Greenwich). 2008;10(9):662-667.
11. Committee on Obstetric Practice. Committee opinion No. 623: emergent therapy for
acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet
Gynecol. 2015;125(2):521-525.
12. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010
ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis
and management of patients with thoracic aortic disease: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines, American Association for Thoracic Surgery, American College of Radiology,
American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for
Cardiovascular Angiography and Interventions, Society of Interventional Radiology,
Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation.
13. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC guidelines on the diagnosis and
treatment of aortic diseases [in Polish]. Kardiol Pol. 2014;72(12):1169-1252.
14. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. Am J
Health Syst Pharm. 2009;66(15):1343-1352.
15. Pedraza R, Marik PE, Varon J. Posterior reversible encephalopathy syndrome: a review.
Crit Care Shock. 2009;12(4):135-143.
16. EC, Saver JL, Adams HP Jr, et al; American Heart Association Stroke Council, Council
on Cardiovascular Nursing, Council on Peripheral Vascular Disease, and Council on
Clinical Cardiology. Guidelines for the early management of patients with acute ischemic
stroke: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2013;44(3):870-947.
17. Keith NM, Wagener HP, Kernohan JW. The syndrome of malignant hypertension. Arch
Intern Med. 1928;41(2):141-188.
18. Stacey AW, Sozener CB, Besirli CG. Hypertensive emergency presenting as blurry
vision in a patient with hypertensive chorioretinopathy. Int J Emerg Med. 2015;8(13). Accessed February
18, 2016.
19. Luo JL, Wu CK, Lin YH, et al. Type A aortic dissection manifesting as acute myocardial
infarction: Still a lesson to learn. Acta Cardiol. 2009;64(4):499-504.
20. OGara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the
management of ST-elevation myocardial infarction: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation. 2013;127(4):e362-e425.
21. Hottinger DG, Beebe DS, Kozhimannil T, Prielipp RC, Belani KG. Sodium nitroprusside
in 2014: a clinical concepts review. J Anaesthesiol Clin Pharmacol. 2014;30(4):462-471.
22. Derhaschnig U, Testori C, Riedmueller E, Hobl EL, Mayr FB, Jilma B. Decreased renal
function in hypertensive emergencies. J Hum Hypertens. 2014; 28(7):427-431.
23. Mouthon L, Brezn A, Bussone G, Nol L-H, Villiger PM, Guillevin L. Scleroderma
renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy
Immunol. 2011;40(2):84-91.
24. Stern EP, Steen VD, Denton CP. Management of renal involvement in scleroderma. Curr
Treatm Opt Rheumatol. 2015;1(1):106-118.
25. Feldstein C. Management of hypertensive crises. Am J Ther. 2007;14(2):135-139.
26. Akimoto T, Muto S, Ito C, et al. Clinical features of malignant hypertension with
thrombotic microangiopathy. Clin Exp Hypertens. 2011;33(2):77-83.